Use of Abciximab and Tirofiban in Patients with Peripheral Arterial Occlusive Disease and Arterial Thrombosis

Abstract

Acute peripheral arterial occlusive disease is an important factor affecting the mobility and mortality rate of elderly patients. Catheter-guided arterial thrombolysis in these patients has its limitations: long lysis times, early occlusions, and high restenosis rates. The study investi gated whether the use of tirofiban has the same favorable effect as the glycoprotein (GP) IIb/IIIa receptor antagonist abciximab and whether lysis times can be shortened and the disease course positively influenced by these substances. Sixty patients were randomly assigned to 2 groups. Each group received 5 mg recombinant tissue-type (rt-PA) plasminogen activator by slow intra-arterial injection for 10 minutes followed by 5 mg rt-PA per hour and 500 IU heparin per hour IV. After randomization 1 group received a bolus of 0.25 mg abciximab per kg body weight followed by 10 mg per minute IV for 12 hours (heparin was reduced to 250 IU/hr). The other group received a bolus of 0.4 μg tirofiban per kg body weight as well as postinterventional medication with 0.1 μg tirofiban per minute and kg body weight for 24 hours. During medication with GP IIb/IIIa inhibitor, the patients received a reduced heparin dosage for 24 hours. After 24 hours both groups received 200 mg aspirin orally and full heparinization controlled on the basis of the partial thromboplastin time. The following efficacy criteria were analyzed: rehospitalization events, reintervention events, and amputations within 6 months. Secondary endpoints were changes in the Fontaine stage, the crurobrachial index, the distance to claudication, and the duration of local arterial lysis. No significant differences were found between the abciximab and tirofiban groups in terms of the rehospitalization, rein tervention, or amputation rates, nor were there any group differences in the total number of events. The secondary parameters, such as the crurobrachial index, distance to claudication, and Fontaine stage, also showed no significant differences between the 2 groups within 6 months. The duration of lysis was significantly shorter in the abciximab group. Major bleeding events did not occur in either group. With regard to the adverse effect rate, there were no significant differences between the 2 groups. Both abciximab and tirofiban can be used successfully in patients with peripheral arterial occlusive disease and arterial thrombosis.

Get full access to this article

View all access options for this article.

References

Adgey Aaj : An overview of the results of clinical trials with glucoprotein IIb/IIa inhibitors . Eur Heart J 19:10-21, 1998.

Chronos N. , Vahanian A. , Betriu A. , et al: Use of abciximab in interventional cardiology. Eur Heart J 19 :31-39, 1998.

Topol EJ , Califf RM , Weismann HF , et al: Randomised trial of coronary intervention with antibody against platelet IIb/IIa integrin for reduction of clinical restenosis: Results at six months. The Lancet 343:881-886, 1994.

Schweizer J. , Kirch W. , Koch R. , et al: Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 51:913-233, 2000.

Adgey Aaj : An overview of the results of clinical trials with glycoprotein IIb/IIa inhibitors . Eur Heart J 19:10-21, 1998.

Kumar A. , Herrmann HC : Tirofiban: An investigational platelet glycoprotein IIb/IIIa receptor antagonist. Ashley Publication, ISSN 1354-3784, 1997. Exp Opin Invest Drugs 6:1257-1267, 1997 .